Product Development PortfolioLast update: July 24, 2014

Therapeutic Area
Partner
Managed By
Compound/
Generic name
Trade name
Indication
Phase
123f
Expected Filing

1. Oncology

1. Oncology
CHU
solid tumors
4. Phase 1

Description/Summary:

A novel small molecule inhibitor to phosphatidylinositol 3-kinase (PI3K) class I.

Managed by:
4. Chugai
Partner:
Roche participation
1. Oncology
RG7116
solid tumors
4. Phase 1

Description/Summary:

RG7116 is a glyco-engineered humanised monoclonal antibody that is designed to inhibit the activation and signalling of HER3, a member of the Human Epidermal Growth Factor Receptor (HER) family which amplifies cell survival and proliferation signals when associated with HER2 or HER1. Through glyco-engineering HER3 MAb is designed to engage the immune system when bound to tumor cells and elicit enhanced antibody-dependent cellular cytotoxicity (ADCC).

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7304
solid tumors
4. Phase 1

Description/Summary:

RG7304 is a small molecule MEK inhibitor with a novel structure based on a coumarin skeleton. It selectively inhibited Raf1 (C-Raf), B-Raf, mutant B-Raf (V600E), and MEK1 in in vitro studies and showed a strong and broad spectrum of antitumor activities both in vitro in various tumor cell lines and in vivo in mouse xenograft models.

Managed by:
2. Pharma Research and Early Development
Partner:
Chugai
1. Oncology
RG7388
solid and hematological tumors
4. Phase 1

Description/Summary:

RG7388 is an oral, selective, small molecule MDM2 antagonist that inhibits binding of MDM2 to p53. Blocking the MDM2-p53 interaction stabilizes p53 and activates p53-mediated cell death and inhibition of cell growth.

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7446
solid tumors
4. Phase 1

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial evaluating anti-PDL1 for solid tumors is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446+Avastin
solid tumors
4. Phase 1

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial evaluating anti-PDL1 in combination with Avastin (bevacizumab) and chemotherapy for solid tumors is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446+Tarceva
non-small cell lung cancer EGFRmut-positive
4. Phase 1

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial evaluating anti-PDL1 in combination with Tarceva (erlotinib) for non-small cell lung cancer with EGFR-activating mutations is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446+Zelboraf
metastatic melanoma
4. Phase 1

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I trial evaluating anti-PDL1 in combination with Zelboraf (vemurafenib) for metastatic melanoma is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446+cobimetinib
solid tumors
4. Phase 1

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase I clinical trial evaluating anti-PDL1 in combination with cobimetinib in locally advanced or metastatic solid tumors is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7450
prostate cancer
4. Phase 1

Description/Summary:

RG7450 (Anti-STEAP1, DSTP3086S) is an antibody drug conjugate (ADC) that consists of a humanized monoclonal antibody directed against STEAP1, a six-transmembrane epithelial antigen of the prostate 1, conjugated to an anti-mitotic agent, monomethyl auristatin E (MMAE). STEAP1 is a membrane protein that is overexpressed in prostate cancer.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7458
ovarian cancer
4. Phase 1

Description/Summary:

RG7458 (Anti-MUC16,DMUC5754A) is an antibody drug conjugate (ADC) composed of a monoclonal antibody directed against MUC16, also known as mucin 16, linked to the small molecule, cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE). MUC16 is a transmembrane protein that can be overexpressed in certain types of cancers.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7600
pancreatic and ovarian cancer
4. Phase 1

Description/Summary:

An antibody drug conjugate (ADC) is a monoclonal antibody that selectively delivers potent anti-cancer agents to tumor cells.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7601
relapsed or refractory chronic lymphocytic leukaemia
4. Phase 1

Description/Summary:

RG7601 is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance.

Managed by:
1. Roche Group
Partner:
Abbott, WEHI
1. Oncology
RG7601+Gazyva
chronic lymphocytic leukemia
4. Phase 1

Description/Summary:

RG7601 is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance

Managed by:
1. Roche Group
Partner:
AbbVie, WEHI
1. Oncology
RG7636
metastatic melanoma
4. Phase 1

Description/Summary:

RG7636 (Anti-ETBR, DEDN6526A) is an antibody drug conjugate (ADC) composed of a monoclonal antibody directed against ETBR, endothelin B receptor, linked to the small molecule, cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE). Endothelin B receptor can be over-expressed in certain types of melanoma.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7666
progressive or recurrent high-grade glioma
4. Phase 1

Description/Summary:

RG7666 (GDC-0084) is a novel, oral, small molecule PI3 kinase inhibitor. PI3 Kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7741
solid tumors or lymphoma
4. Phase 1

Description/Summary:

Checkpoint kinase 1 (ChK1) is a protein kinase that regulates tumor cells' response to DNA damage, often caused by treatment with chemotherapy. In response to DNA damage, ChK1 blocks cell cycle progression in order to allow for repair of damaged DNA. Inhibiting ChK1 in combination with chemotherapy may enhance tumor cell death by preventing these cells from recovering from DNA damage. RG7741 (GDC-0575) is a small molecule ChK1 selective inhibitor designed to prevent tumor cells from recovering from DNA damage.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7775
acute myeloid leukemia
4. Phase 1

Description/Summary:

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7813
solid tumors
4. Phase 1

Description/Summary:

RG7813 is a targeted immunocytokine combining an engineered cytokine (IL2v) with an antibody against carcinoembryonic antigen (CEA), a protein expressed in several cancers. A phase I clinical trial evaluating RG7813 in solid tumors is ongoing.

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7841
solid tumors
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating the antibody drug conjugate RG7841 in solid tumors is ongoing.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7842
solid tumors
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7842 (GDC-0094) in solid tumors is ongoing.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7845
hematological tumors
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7845 (GDC-0853) in B-cell lymphoma and chronic lymphocytic leukemia is ongoing.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7882
ovarian cancer
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating the antibody drug conjugate RG7882 in platinum-resistant ovarian cancer or unresectable pancreatic cancer is ongoing.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG3616 vismodegib
Erivedge
acute myelogenous leukemia
3. Phase 2
2017+

Description/Summary:

Vismodegib is an oral, small molecule targeted medicine designed to selectively inhibit abnormal signaling in the Hedgehog pathway, which is an underlying molecular driver of BCC.

Managed by:
1. Roche Group
Partner:
Curis
1. Oncology
RG7155
solid tumors & pigmented villonodular synovitis
3. Phase 2
2017+

Description/Summary:

RG7155 is a humanized monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R) designed to inhibit the CSF-1 mediated survival of tumor-promoting ‘M2’ macrophages without affecting tumor-killing ‘M1’ macrophages.

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7221
colorectal cancer
3. Phase 2
2017+

Description/Summary:

RG7221 is a bi-specific monoclonal antibody comprised of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.

Managed by:
2. Pharma Research and Early Development
Roche Only
1. Oncology
RG7321 pictilisib
solid tumors
3. Phase 2
2017+

Description/Summary:

Pictilisib is a PI3 kinase inhibitor currently investigated in a phase II clinical trial. PI3 kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7440 ipatasertib
solid tumors
3. Phase 2
2017+

Description/Summary:

RG7440 is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Managed by:
3. Genentech Research and Early Development
Partner:
Array BioPharma
1. Oncology
RG7446
metastatic urothelial bladder cancer
3. Phase 2
2016

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase II trial evaluating anti-PDL1 for locally advanced or metastatic urothelial bladder cancer is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446
metastatic non-small cell lung cancer
3. Phase 2
2016

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7446+Avastin
renal cell cancer
3. Phase 2
2017+

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase II trial evaluating anti-PDL1 in combination with Avastin (bevacizumab) for renal cell cancer is ongoing.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7593 pinatuzumab vedotin
hematological malignancies
3. Phase 2
2017+

Description/Summary:

Anti-CD22 is an antibody drug conjugate (ADC) that consists of a humanized IgG1 anti-CD22 monoclonal antibody, conjugated to a anti-mitotic agent, monomethyl auristatin E (MMAE).

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7596 polatuzumab vedotin
hematological malignancies
3. Phase 2
2017+

Description/Summary:

Anti-CD79b is an antibody drug conjugate (ADC) that consists of a monoclonal antibody, conjugated to a potent anti-cancer agent that is selectively delivered to tumor cells.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7597
metastatic epithelial tumors
3. Phase 2
2017+

Description/Summary:

Anti-HER3/EGFR, a dual action antibody, is a phage-derived, human IgG1 monoclonal antibody that is designed to target human epidermal growth factor receptor 3 (HER3) and epidermal growth factor receptor (EGFR).

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7599
platinum-resistant ovarian cancer
3. Phase 2
2017+

Description/Summary:

RG7599 (Anti-NaPi2b, DNIB0600A) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody directed against NaPi2b, sodium-dependent phosphate transport protein 2b, linked to the small molecule, cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE). NaPi2b can be overexpressed in certain types of cancer.

Managed by:
3. Genentech Research and Early Development
Partner:
Seattle Genetics
1. Oncology
RG7601
Front-line Diffuse large B-cell lymphoma
3. Phase 2
2017+

Description/Summary:

RG7601 is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance.

Managed by:
1. Roche Group
Partner:
AbbVie/WEHI
1. Oncology
RG7601
relapsed/refractory chronic lymphocytic leukemia 17p deletion
3. Phase 2
2016+

Description/Summary:

RG7601 is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance.

Managed by:
1. Roche Group
Partner:
Abbott, WEHI
1. Oncology
RG7604 taselisib
solid tumors
3. Phase 2
2017+

Description/Summary:

PI3 Kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Managed by:
3. Genentech Research and Early Development
Roche Only
1. Oncology
RG7686
metastatic liver cancer
3. Phase 2
2017+

Description/Summary:

RG7686 is a first in class monoclonal humanized anti-glypican 3 antibody being developed as single agent and in combination against metastatic hepatocellular carcinoma. Its therapeutic activity in pre-clinical models was shown to take place via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Managed by:
2. Pharma Research and Early Development
Partner:
Chugai
1. Oncology
RG7853 alectinib
non-small cell lung cancer
3. Phase 2
2017+

Description/Summary:

RG7853 is a small molecule that is designed to inhibit anaplastic lymphoma kinase (ALK) involved in the pathology of non-small cell lung cancer.

Managed by:
2. Pharma Research and Early Development
Partner:
Chugai
1. Oncology
RG1273 pertuzumab
Perjeta
2nd line HER2-positive breast cancer
2. Phase 3
2016

Description/Summary:

Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with Herceptin and chemotherapy is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG1273 pertuzumab
Perjeta
advanced HER2-positive gastric cancer
2. Phase 3
2017+

Description/Summary:

Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with Herceptin and chemotherapy is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG1273 pertuzumab
Perjeta
early HER2-positive breast cancer
2. Phase 3
2016

Description/Summary:

Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with Herceptin and chemotherapy is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG3502 trastuzumab emtansine + pertuzumab
Kadcyla + Perjeta
early HER2-positive BC adj
2. Phase 3
2017+

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors. Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with T-DM1 is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Partner:
Immunogen
1. Oncology
RG3502 trastuzumab emtansine + pertuzumab
Kadcyla + Perjeta
early HER2-positive BC neoadj
2. Phase 3
2017+

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors. Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with T-DM1 is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Partner:
Immunogen
1. Oncology
RG3502 trastuzumab-DM1
Kadcyla
advanced HER2-positive gastric cancer
2. Phase 3
2015

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.

Managed by:
1. Roche Group
Partner:
ImmunoGen
1. Oncology
RG3502 trastuzumab-DM1
Kadcyla
early HER2-positive breast cancer adj
2. Phase 3
2017+

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.

Managed by:
1. Roche Group
Partner:
ImmunoGen
1. Oncology
RG3502 trastuzumab-DM1 + pertuzumab
Kadcyla + Perjeta
1st line HER2-positive metastatic breast cancer
2. Phase 3
2015

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors. Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. The goal of combining pertuzumab with T-DM1 is to determine if the combination may provide a more comprehensive blockade of HER signalling pathways.

Managed by:
1. Roche Group
Partner:
ImmunoGen
1. Oncology
RG435 bevacizumab
Avastin
1st line metastatic ovarian cancer
2. Phase 3
2014 US

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG435 bevacizumab
Avastin
adjuvant non-small cell lung cancer
2. Phase 3
2017+

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG435 bevacizumab
Avastin
relapsed ovarian cancer, platinum-sensitive
2. Phase 3
2014 US

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7159 obinutuzumab
Gazyva
diffuse large B-cell lymphoma
2. Phase 3
2016

Description/Summary:

Obinutuzumab, GA101, is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration.

Managed by:
1. Roche Group
Partner:
Biogen Idec
1. Oncology
RG7159 obinutuzumab
Gazyva
front-line indolent non-Hodgkin's lymphoma
2. Phase 3
2017+

Description/Summary:

Obinutuzumab, GA101, is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration.

Managed by:
1. Roche Group
Partner:
Biogen Idec
1. Oncology
RG7159 obinutuzumab
Gazyva
refractory indolent Non Hodgkin's lymphoma
2. Phase 3
2017+

Description/Summary:

Obinutuzumab, GA101, is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration.

Managed by:
1. Roche Group
Partner:
Biogen Idec
1. Oncology
RG7204 vemurafenib
Zelboraf
adjuvant metastatic melanoma, BRAF mutation positive
2. Phase 3
2017+

Description/Summary:

Zelboraf is an oral, small molecule, BRAF kinase inhibitor. The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that keep the BRAF protein in an active state may cause excessive pathway signalling, leading to uncontrolled cell growth and survival.

Managed by:
1. Roche Group
Partner:
Plexxikon Inc., member of Daiichi Sankyo Group
1. Oncology
RG7421+RG7204 cobimetinib combo
metastatic melanoma BRAF mutation positive
2. Phase 3
2014

Description/Summary:

RG7421, a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors. Inappropriate activation of the MEK/ERK pathway promotes cell growth in the absence of exogenous growth factors. Combination study with the oral, small molecule, BRAF kinase inhibitor Zelboraf.

Managed by:
1. Roche Group
Partner:
Exelixis
1. Oncology
RG7446
2nd line non-small cell lung cancer
2. Phase 3
2016

Description/Summary:

Tumor immunotherapy is the use of the immune system to reject cancer. Anti-PDL1 (RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7601+MabThera/Rituxan
relapsed/refractory chronic lymphocytic leukemia
2. Phase 3
2016

Description/Summary:

RG7601 is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance. A phase III clinical trial evaluating the combination of RG7601 and MabThera/Rituxan (rituximab) in relapsed or refractory chronic lymphocytic leukemia is ongoing.

Managed by:
1. Roche Group
Partner:
AbbVie, WEHI
1. Oncology
RG435 bevacizumab
Avastin
recurrent cervical cancer
1. Filed
2014

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG435 bevacizumab
Avastin
relapsed ovarian cancer, platinum-resistant
1. Filed
2013 EU

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG435 bevacizumab
Avastin
1st line glioblastoma multiforme
1. Filed
2013 EU

Description/Summary:

Avastin is a monoclonal antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis – a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body.

Managed by:
1. Roche Group
Roche Only
1. Oncology
RG7159 obinutuzumab
front-line chronic lymphocytic leukemia
1. Filed
2013

Description/Summary:

Obinutuzumab, GA101, is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration.

Managed by:
1. Roche Group
Partner:
Biogen Idec
1. Oncology
RG105 rituximab
MabThera / Rituxan
non-Hodgkin's lymphoma subcutaneous formulation
2012 EU

Description/Summary:

Rituxan is a monoclonal antibody that binds to a specific protein called CD20 found on the surface of cancerous and normal B-cells. Rituxan works with the body's own immune system to eliminate CD20-positive B-cells. Stem cells (B-cell progenitors that give rise to B-cells) in bone marrow do not have the CD20 protein allowing B-cells to repopulate after Rituxan treatment.

Managed by:
1. Roche Group
Partner:
Biogen Idec, Halozyme
1. Oncology
RG3502 trastuzumab-DM1
Kadcyla
pretreated HER2-positive metastatic breast cancer
2012

Description/Summary:

Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.

Managed by:
1. Roche Group
Partner:
ImmunoGen

2. Immunology

2. Immunology
RG7624
autoimmune disease
4. Phase 1

Description/Summary:

RG7624 is a fully human monoclonal antibody designed to specifically and selectively bind to the human interleukin-17 family of cytokines. A Phase I clinical trial evaluating RG6724 for autoimmune disease is ongoing.

Managed by:
3. Genentech Research and Early Development
Partner:
NovImmune
2. Immunology
CHU
atopic dermatitis
3. Phase 2

Description/Summary:

CIM331 is a humanized monoclonal antibody. It is currently investigated as a therapy for atopic dermatitis.

Managed by:
4. Chugai
Partner:
Roche participation
2. Immunology
RG1569 tocilizumab
Actemra / RoActemra
systemic sclerosis
3. Phase 2
2017+

Description/Summary:

Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 , a protein that plays a major role in the systemic sclerosis inflammation process.

Managed by:
1. Roche Group
Partner:
Chugai
2. Immunology
RG3637 lebrikizumab
idiopathic pulmonary fibrosis
3. Phase 2
2017+

Description/Summary:

Lebrikizumab is a novel humanized monoclonal antibody designed to specifically block the action of the interleukin-13 cytokine (a signalling protein that serves as a messenger between cells that is increased in some patients with asthma) and so reduce airway inflammation, a key feature of asthma.

Managed by:
1. Roche Group
Roche Only
2. Immunology
RG7449 quilizumab
asthma
3. Phase 2
2017+

Description/Summary:

Quilizumab is a humanized monoclonal antibody, targeting the IgE pathway, that binds to the M1 prime segment of membrane IgE. Anti-M1 prime is designed to eliminate the B cells that would develop into plasma cells and produce IgE, rather than binding to and neutralizing existing IgE.

Managed by:
3. Genentech Research and Early Development
Roche Only
2. Immunology
CHU sodium hyaluronate
Suvenyl
enthesopathy
2. Phase 3

Description/Summary:

A phase III study in enthesopathy (lateral epicondylitis, patellar tendinitis, achilles tendinopathy, and plantar fasciitis) is ongoing to evaluate the reduction of pain by Suvenyl due to the alleviation of stress occurring where tendon and ligament meet the bone.

Managed by:
4. Chugai
Partner:
Roche participation
2. Immunology
CHU
neuromyelitis optica
2. Phase 3

Description/Summary:

A humanized monoclonal antibody to the interleukin-6 receptor.

Managed by:
4. Chugai
Partner:
Roche participation
2. Immunology
RG1569 tocilizumab
Actemra / RoActemra
giant cell arteritis
2. Phase 3
2016

Description/Summary:

Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6. Elevated tissue and serum levels of IL-6 have been implicated in giant cell arteritis (GCA). Inhibition of IL-6 therefore represents a new and novel approach for the treatment of GCA.



Managed by:
1. Roche Group
Partner:
Chugai
2. Immunology
RG3637 lebrikizumab
severe asthma
2. Phase 3
2016

Description/Summary:

Lebrikizumab is a novel humanized monoclonal antibody designed to specifically block the action of the interleukin-13 cytokine (a signalling protein that serves as a messenger between cells that is increased in some patients with asthma) and so reduce airway inflammation, a key feature of asthma.

Managed by:
1. Roche Group
Roche Only
2. Immunology
RG7413 etrolizumab
ulcerative colitis
2. Phase 3
2017+

Description/Summary:

Etrolizumab is a humanized IgG1 MAb targeting the beta 7 integrin subunit. It binds to two integrin receptors, alpha4beta7 and alphaEbeta7. These receptors are required for trafficking and retention in lymphocytes in the gastrointestinal tract and appear to play a role in inflammatory bowel diseases.

Managed by:
3. Genentech Research and Early Development
Roche Only
2. Immunology
RG1569 tocilizumab
Actemra / RoActemra
early rheumatoid arthritis
1. Filed
2013 EU

Description/Summary:

Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 , a protein that plays a major role in the rheumatoid arthritis inflammation process.

Managed by:
1. Roche Group
Partner:
Chugai
2. Immunology
RG3648 omalizumab
Xolair
chronic idiopathic urticaria
2013 US

Description/Summary:

Xolair is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E), an underlying component of allergic asthma. Xolair is designed to bind to the circulating IgE antibodies in the blood, decreasing the amount of IgE antibodies available to bind to mast cells. With Xolair, fewer IgE antibodies can bind to mast cells, making IgE cross-linking less likely and inhibiting the mast cell's release of those chemicals that can lead to the symptoms of asthma.

Managed by:
1. Roche Group
Partner:
Novartis

3. Ophthalmology

3. Ophthalmology
RG3645 ranibizumab
Lucentis
sustained delivery age-related macular degeneration/retinal vein occlusion/diabetic macular edema
4. Phase 1

Description/Summary:

Lucentis is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. In DME, damaged blood vessels leak fluid into the central portion of the retina, called the macula, causing it to swell. The macula is the part of the eye responsible for sharp central vision.

Managed by:
1. Roche Group
Partner:
Novartis, ForSight VISION4
3. Ophthalmology
RG7716
wet age-related macular degeneration
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7716 in wet age-related macular degeneration is ongoing.

Managed by:
2. Pharma Research and Early Development
Roche Only
3. Ophthalmology
RG7417 lampalizumab
geographic atrophy associated with AMD
3. Phase 2
2017+

Description/Summary:

Lampalizumab (anti-Factor D Fab) is a humanized monoclonal antibody fragment targeting complement factor D. It is designed to inhibit complement activation and chronic inflammation in tissues. Complement Factor D is a member of the trypsin family of peptidases and is a component of the alternative complement pathway.

Managed by:
3. Genentech Research and Early Development
Roche Only

4. Infectious Diseases

4. Virology
RG7128 mericitabine
hepatitis C
3. Phase 2
2017+

Description/Summary:

Mericitabine is an oral, small molecule nucleoside analog NS5B RNA-dependent RNA polymerase inhibitor of hepatitis C viral replication. Intracellular mericitabine is phosphorylaed to two distinct active triphosphates. These triphosphates disable an enzyme required to copy hepatitis C virus RNA, hence viral replication is halted.

Managed by:
1. Roche Group
Partner:
Pharmasset
4. Virology
RG7227 danoprevir
hepatitis C
3. Phase 2
2017+

Description/Summary:

Danoprevir is a macrocyclic peptidomimetic small molecule compound that competitively inhibits the HCV NS3/4A protease.

Managed by:
2. Pharma Research and Early Development
Roche Only
4. Virology
RG7667
CMV disease
3. Phase 2
2017+

Description/Summary:

A Phase II clinical trial in CMV disease is ongoing.

Managed by:
3. Genentech Research and Early Development
Roche Only
4. Virology
RG7745
influenza A
3. Phase 2
2017+

Description/Summary:

RG7745 (Anti-Influenza A, MHAA4549A) is a human monoclonal antibody that binds to a highly conserved epitope on the influenza A hemagglutinin stalk region, which is designed to neutralize the influenza A virus across a broad range of different strains. A Phase IIa clinical trial evaluating RG7745 in an influenza challenge model in ongoing.

Managed by:
3. Genentech Research and Early Development
Roche Only
4. Virology
RG7790 setrobuvir
hepatitis C
3. Phase 2
2016

Description/Summary:

Setrobuvir is a potent small molecule non-nucleoside inhibitor of the hepatitis C virus genotype 1 NS5b RNA polymerase.

Managed by:
2. Pharma Research and Early Development
Roche Only
4. Virology
RG7929
antibiotic
3. Phase 2
2017+

Description/Summary:

RG7929 (POL7080) is an antibiotic designed to target multi-drug resistant bacterial strains of Pseudomonas aeruginosa (PA). By targeting the lipopolysaccharide-assembly protein (LptD) located on the outer membrane of PA, RG7929 is thought to interfere with the synthesis of the bacterial cell wall. A phase II clinical trial evaluating RG7929 as antibacterial therapy is ongoing.

Managed by:
2. Pharma Research and Early Development
Partner:
Polyphor

5. CardioMetabolism

5. CardioMetabolism
CHU
gout
4. Phase 1

Description/Summary:

URC102 is a small molecule inhibitor of the urate transporter protein URAT1. The target indication of URC102 is gout. The compound is expected to reduce the level of serum uric acid by promoting its excretion through inhibition of URAT1. A phase I clinical trial with healthy volunteers is ongoing. URC102 is under co-development by Chugai and JW Pharmaceutical.

Managed by:
4. Chugai
Partner:
Roche participation
5. CardioMetabolism
RG7410
metabolic diseases
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7410 for metabolic disease is ongoing.

Managed by:
2. Pharma Research and Early Development
Roche Only
5. CardioMetabolism
RG7641
kidney disease
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7641 in kidney disease is ongoing.

Managed by:
2. Pharma Research and Early Development
Roche Only
5. CardioMetabolism
RG7697
type 2 diabetes
4. Phase 1

Description/Summary:

RG7697 is a dual agonist peptide analogue with biologic homology to both GLP-1 and GIP for the treatment of type 2 diabetes. GLP-1 and GIP are incretin hormones involved in glucose homeostasis as well as regulation of other metabolic processes.

Managed by:
2. Pharma Research and Early Development
Roche Only
5. CardioMetabolism
RG1512 inclacumab
acute coronary syndrome/cardiovascular disease
3. Phase 2

Description/Summary:

Inclacumab is a fully human monoclonal Ab designed to neutralize P-selectin, a multifunctional molecule at the interface of inflammation and thrombosis. By inhibiting both inflammatory and thrombotic reactions, anti-P-selectin could be an effective therapy for cardiovascular diseases.

Managed by:
2. Pharma Research and Early Development
Partner:
Genmab

6. Neuroscience

6. Neuroscience
RG7203
schizophrenia
4. Phase 1

Description/Summary:

RG7203 is a highly potent and selective small molecule inhibitor of phosphodiesterase 10A (PDE10A). RG7203 has demonstrated efficacy in preclinical animal models of psychiatric disorders, especially schizophrenia.

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG7342
schizophrenia
4. Phase 1

Description/Summary:

RG7342 is a highly potent and selective small molecule positive allosteric modulator targeting the glutamatergic system in the brain. RG7342 has demonstrated efficacy in preclinical animal models of psychiatric disorders, especially schizophrenia

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG7800
spinal muscular atrophy
4. Phase 1

Description/Summary:

A phase I clinical trial evaluating RG7800, a novel small molecule SMN2 splicing modifier, is ongoing.

Managed by:
2. Pharma Research and Early Development
Partner:
PTC Therapeutics/ SMA Foundation
6. Neuroscience
RG7935
Parkinson's disease
4. Phase 1

Description/Summary:

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG1577
Alzheimer's disease
3. Phase 2
2017+

Description/Summary:

RG1577 is a potent small molecule inhibitor of monoamine oxidase-B (MAO-B) which reduces the formation of toxic reactive oxygen species in the brain of Alzheimer’s disease patients where overexpression of MAO-B is postulated to contribute to neuronal damage.

Managed by:
2. Pharma Research and Early Development
Partner:
Evotec
6. Neuroscience
RG1578 decoglurant
depression
3. Phase 2
2017+

Description/Summary:

RG1578 is a small molecule negative modulator of metabotropic glutamate 2/3 receptor that plays an important role in affective and cognitive functions in the central nervous system. RG1578 has exhibited robust antidepressant and cognitive enhancing effects in a broad range of preclinical models and is currently studied for the treatment of depressive disorders.

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG1662
Down syndrome
3. Phase 2
2017+

Description/Summary:

RG1662 is a small molecule negative allosteric modulator that acts on a specific subset of receptors called gamma-aminobutyric acid (GABA) A receptors alpha 5, GABRA5. They are present in discrete brain regions associated with cognitive processing. A relative increase in GABAergic tone is believed to be present in people with Down syndrome and responsible for cognitive disability.

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG1678 bitopertin
obsessive compulsive disorder
3. Phase 2
2017+

Description/Summary:

Bitopertin is an oral, small molecule first-in-class glycine reuptake inhibitor (GRI). Bitopertin enhances N-methyl-D-aspartate (NMDA) receptor activity, thereby targeting an important pathway in the treatment of psychiatric disorders, especially schizophrenia.

Managed by:
1. Roche Group
Roche Only
6. Neuroscience
RG7090 basimglurant
treatment-resistant depression
3. Phase 2
2017+

Description/Summary:

RG7090 is a small molecule negative modulator of metabotropic glutamate receptor 5 (mGluR5), a receptor in the central nervous system regulating neurotransmitter release, signal transduction, mood and memory formation. Preclinical data has suggested that modulation of mGluR5 functioning is expected to play an important therapeutic role in depression and Fragile X syndrome.

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG7314
autism
3. Phase 2
2017+

Description/Summary:

RG7314 is a potent and specific small molecule antagonist of the V1A vasopressin receptor, which is implicated in modulating emotional processing and key social deficits exhibited in patients with Autism spectrum disorders.

Managed by:
2. Pharma Research and Early Development
Roche Only
6. Neuroscience
RG7412 crenezumab
Alzheimer's disease
3. Phase 2
2017+

Description/Summary:

Crenezumab is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease and is proposed to be causative in the development of the disease.

Managed by:
3. Genentech Research and Early Development
Partner:
AC Immune
6. Neuroscience
RG1450 gantenerumab
Alzheimer's disease
2. Phase 3
2017+

Description/Summary:

Gantenerumab is a fully human monoclonal antibody that binds and neutralises disease-relevant aggregated forms of amyloid-beta: those that accumulate as plaques in the brain and those which interfere with brain-cell functioning.

Managed by:
1. Roche Group
Partner:
Morphosys
6. Neuroscience
RG1594 ocrelizumab
primary progressive multiple sclerosis
2. Phase 3
2015

Description/Summary:

Ocrelizumab is a humanized monoclonal antibody that selectively targets the CD20-positive B-cells implicated in the inflammatory and neurodegenerative processes of multiple sclerosis (MS), to effectively impact disease progression while maintaining immunosurveillance.

Managed by:
1. Roche Group
Roche Only
6. Neuroscience
RG1594 ocrelizumab
relapsing multiple sclerosis
2. Phase 3
2015

Description/Summary:

Ocrelizumab is a humanized monoclonal antibody that selectively targets the CD20-positive B-cells implicated in the inflammatory and neurodegenerative processes of multiple sclerosis (MS), to effectively impact disease progression while maintaining immunosurveillance.

Managed by:
1. Roche Group
Roche Only
6. Neuroscience
RG1678 bitopertin
schizophrenia; suboptimally controlled symptoms
2. Phase 3

Description/Summary:

Bitopertin is an oral, small molecule first-in-class glycine reuptake inhibitor (GRI). Bitopertin enhances N-methyl-D-aspartate (NMDA) receptor activity, thereby targeting an important pathway in the treatment of psychiatric disorders, especially schizophrenia.

Managed by:
1. Roche Group
Roche Only

7. Other

7. Other
RG6013
hemophilia A
3. Phase 2
2017+

Description/Summary:

RG6013/ACE910 is a bispecific antibody that mimics coagulation factor VIII, an essential blood clotting protein. It is currently investigated as a therapy for people with hemophilia A, a congenital bleeding disorder that is caused by deficiency or dysfunction of coagulation factor VIII.

Managed by:
1. Roche Group
Partner:
Chugai

No results

Sorry, the filter or keyword combination yields no results.

Try removing some filters or search for another keyword.

loading
Phase 1
Phase 2
Phase 3
Filed
Approved
00

New / Advanced

 
 

RG7775

acute myeloid leukemia

acute myeloid leukemia

 
 

RG7882

ovarian cancer

ovarian cancer

 
 

RG7155

solid tumors & PVNS

solid tumors & pigmented villonodular synovitis

 
 

RG7221

colorectal cancer

colorectal cancer

 
 

RG7601

Diffuse large B-cell lymphoma

Front-line Diffuse large B-cell lymphoma

 
 

RG7604

solid tumors

solid tumors

 
 

RG3502

Kadcyla + Perjeta

HER2-positive BC adj

early HER2-positive BC adj

 
 

RG3502

Kadcyla + Perjeta

HER2-positive BC neoadj

early HER2-positive BC neoadj

 
 

RG435

Avastin

recurrent cervical cancer

recurrent cervical cancer

 
 

CHU

RA

neuromyelitis optica

 
 

RG7413

ulcerative colitis

ulcerative colitis

 
 

RG1569

Actemra / RoActemra

RA sc formulation

rheumatoid arthritis, subcutaneous formulation

 
 

RG7342

schizophrenia

schizophrenia

 
 

RG7935

Parkinson's disease

Parkinson's disease

 
 

RG1662

Down syndrome

Down syndrome

00

Removed

 
 

RG3638

hepatocellular carcinoma

hepatocellular carcinoma

 
 

RG7167

solid tumors

solid tumors

 
 

RG7598

multiple myeloma

multiple myeloma

 
 

RG3638

mCRC

metastatic colorectal cancer

 
 

RG3638

met HER2-negative gastric cancer

metastatic HER2-negative gastric cancer

 
 

RG435

Avastin

adj BC, HER2-neg

adjuvant breast cancer, HER2-negative

 
 

RG435

Avastin

high-risk carcinoid

high-risk carcinoid

 
 

RG7415

SLE

systemic lupus erythematosus

 
 

RG3806

acromegaly

acromegaly

 
 

RG7863

hepatitis B

hepatitis B

 
 

RG7652

metabolic disease

metabolic disease

 
CardioMetabolism
 
Immunology
 
Neuroscience
 
Oncology
 
Ophthalmology
 
Virology
 
Other
Area
Product name
Description
Market

Instruments/devices planned for 2014

Laboratories
cobas 6800/8800
next generation molecular (PCR) system
WW*
cobas m511
fully integrated and automated hematology system
EU
cobas 6500
automated urinalysis work area
EU
Connect-V
middleware providing connectivity to LIS1
WW*
Diabetes Care
Accu-Chek Insight
next generation insulin pump & bGm2 system
EU
Accu-Chek Connect
bg meter with connectivity to smartphones, mobile app and cloud
EU

Tests/assays planned for 2014

Blood screening / Infectious diseases
MPX2.0
next generation blood screening multiplex test
US
MPX (HIV, HCV, HBV), HEV, DPX3, WNV4
full NAT blood screening menu for cobas 6800/8800
WW*
HIV, HCV, HBV
virology tests for cobas 6800/8800
WW*
HSV
detection of Herpes Simplex Virus on cobas 4800
EU
Syphillis
immunoassay for the detection of Treponema pallidum
EU
Microbiology
MRSA/SA
next generation test on cobas 4800
EU
C-difficile
diagnosis of clostridium infections
EU
Women's Health
AMH
assessment of ovarian reserve for fertility
EU
PE Prognosis
claim extension for short-term prediction of preeclampsia in pregnancy
EU

Area
Market

* excluding US.
1 hospital information systems.
2 blood glucose monitoring.
3 parvovirus B19 and hepatitis A virus.
4 west nile virus.